Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Associate Editor for Breast Cancer at ESMO Open, shared a post on X by Kohei Shitara, Director of the Department of Gastrointestinal Oncology at National Cancer Center Hospital Eas, adding:
“From HER2-low breast cancer to HER2-low gastric cancer – looking forward to seeing the trial results”
Quoting Kohei Shitara‘s post:
“Protocol of IIT for T-DXd+1st-line chemo+nivolumab for HER2 low gastric/GEJ cancer is published at ESMO Gastrointestinal Oncology. The enrollment is already completed, and the results will be reported in the near future”
Title: An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma
Authors: Y. Aoki, I. Nakayama, Y. Komura, M. Wakabayashi, S. Fukuoka, H. Hara, H. Shoji, M. Furuta, K. Minashi, A. Sato, N. Fuse, N. Sakamoto, T. Kuwata, K. Shitara
Read the Full Article in Science Direct.
More posts featuring Paolo Tarantino on OncoDaily.